Merck Suffers Blow Developing New Migraine Drug
Telcagepant has been eagerly anticipated by many of us in the migraine world as a possible alternative to triptans and ergotamines for treating viscious migraine attacks. Now it seems Merck has decided against its long-held intention to seek FDA approval of the drug this year. Some speculate it may even completely abandon the product.
The problem: some patients participating in an exploratory study gauging whether the drug could be taken daily to prevent migraines developed high levels of liver enzymes. The company stopped the study and is reviewing data from another study, said Peter Kim, Merck’s research chief. Meantime, it is moving ahead with studies of the drug’s intermittent use to treat migraine attacks.It is completely unclear at this point what this news might mean for the future of CGRP-related research and drugs intended to target this neuropeptide released by the brain during a migraine attack.
Telcagepant & The Future of Migraine Prevention
Possible Genetic Explanation for Migraine
Migraine News Roundup 34
Technorati Tags: news, research, policy, fda, medication, depression, migraines, chronic illness, health, somebody heal me
Subscribe to the Somebody Heal Me feed: Subscribe in a reader or subscribe by e-mail.
Content by Diana E. Lee.